Kringle Pharma (TSE:4884) Other Current Payables: 円88.47 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4884 Kringle Pharma Inc TSE:4884
40 GF Score
Price 円317.00
GF Value 円489.64
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Other Current Payables?

Kringle Pharma TSE:4884 -2.46% 40 Other Current Payables is 円88.47 Mil as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 40/100 and a GF Value™ of 円489.64 (Possible Value Trap). The stock has 5 warning signs investors should review.

Kringle Pharma's Other Current Payables for the quarter that ended in Mar. 2026 was 円88.47 Mil.

Kringle Pharma's quarterly Other Current Payables increased from Sep. 2025 (円20.32 Mil) to Dec. 2025 (円28.51 Mil) and increased from Dec. 2025 (円28.51 Mil) to Mar. 2026 (円88.47 Mil).

Kringle Pharma's annual Other Current Payables declined from Sep. 2023 (円171.66 Mil) to Sep. 2024 (円36.44 Mil) and declined from Sep. 2024 (円36.44 Mil) to Sep. 2025 (円20.32 Mil).

Kringle Pharma Other Current Payables Related Terms

Kringle Pharma Other Current Payables Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Other Current Payables Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Current Payables
Get a 7-Day Free Trial 30.97 52.86 171.66 36.44 20.32

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.79 28.51 20.32 28.51 88.47
TSE:4884
40GF Score
Kringle Pharma Inc TSE:4884
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of 円88.47 Mil mean?
Kringle Pharma (TSE:4884) has a Other Current Payables of 円88.47 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Kringle Pharma and its competitors.
Is Kringle Pharma's Other Current Payables too high?
Kringle Pharma's current Other Current Payables is 円88.47 Mil. Overall, Kringle Pharma has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Other Current Payables compare to VRTX and REGN?
Kringle Pharma's Other Current Payables of 円88.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Other Current Payables is 円88.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円489.64, compared to a current price of 円317.00 — trading 35.3% below its estimated fair value. The current Other Current Payables is 円88.47 Mil. Kringle Pharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Other Current Payables is 円88.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円317.00 is trading 35.3% below its estimated GF Value™ of 円489.64. GuruFocus considers Kringle Pharma to be Possible Value Trap.

Key valuation signals for TSE:4884:

  • Other Current Payables: 円88.47 Mil
  • GF Value™: 円489.64 vs. price of 円317.00 (35.3% below fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
40GF Score

Get the complete analysis for TSE:4884

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円317.00
Price
円489.64
GF Value